Search over 3,000 reports

    Natural Killer Cells -Competitive Landscape, Technology and Pipeline Analysis, 2017

    Natural Killer Cells -Competitive Landscape, Technology and Pipeline Analysis, 2017
    Date: Aug, 2017
    Type: Pharmaceutical Industry Report
    Pages: 207
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DISR0004

    DelveInsight's, "Natural Killer Cells- Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Natural Killer Cells.
    This report provides information on the therapeutic development based on Natural Killer Cells mechanism of action dealing with around 40+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight's Report also assesses the Natural Killer Cells therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 22+ active companies involved in the therapeutic development of the products.
    Scope
    - The report provides competitive pipeline landscape of Natural Killer Cells
    - The report provides the marketed drugs information including its sales, development activities and details of patent expiry
    - The report provides the insight of current and future market for Natural Killer Cells
    - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
    - Coverage of the Natural Killer Cells pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
    - The report reviews key players involved in the therapeutics development for Natural Killer Cells and also provide company profiling
    - The report also gives the information of dormant pipeline projects
    - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
    - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
    '
    Reasons to Buy
    - Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
    - Complete MOA intelligence and complete understanding over therapeutics development for Natural Killer Cells
    - Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
    - Devise corrective measures for pipeline projects by understanding Natural Killer Cells pipeline depth and focus of Indication therapeutics
    - Developing strategic initiatives to support your drug development activities.
    - Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
    - Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    - Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

    Executive Summary Snapshot Report
    Executive Summary
    Natural Killer Cells Overview
    Analysis of NK cells based therapies
    NK Cells Receptors and Shares
    Percentage Share of NK Cell Based Therapeutics
    Targets of Natural Killer Cells Based Therapies and Their Analysis
    NK Cells Based Therapy Collaborations
    Collaborations and Deal Year
    Collaborations and Deal value
    Licensing Agreement for future development of NK Cell Therapy
    Financing details of NK cells based therapies
    Companies received Grants for NK cells based therapies
    Designation
    Institutes involved in NK cells based therapies
    Technologies Involved in NK Cells Based Therapies
    Clinical trials & Completion Year
    Phase III Drugs
    Phase II Drugs
    Phase I Drugs
    Recent Trends in NK Cells Therapy
    Leading Companies and their Shares in Natural Killer cells Therapeutics
    Market Drivers
    Market Barriers
    SWOT Analysis
    Pipeline Therapeutics
    Therapeutics under Development by Companies
    Late Stage Products (Phase III)
    Comparative Analysis
    Mid Stage Products (Phase II)
    Comparative Analysis
    Early Stage Products (Phase I and IND)
    Comparative Analysis
    Pre-Clinical and Discovery Products
    Comparative Analysis
    Therapeutic Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Route of Administration
    Assessment by Stage and Route of Administration
    Assessment by Molecule Type
    Assessment by Stage and Molecule Type
    Assessment by Domain
    Assessment by Stage and Domain
    Appendix
    Report Methodology
    DelveInsight Consulting Services
    About DelveInsight
    Contact Us
    Disclaimer

    Table 1: Receptors of NK cells
    Table 2:Type of NK Cells Receptors
    Table 3:Targets and Number of Products
    Table 4:Natural Killer Cells based therapies -Target Antigens and Companies
    Table 5:Collaboration and Deal Values for NK cell therapy, 2017
    Table 6: Licensing Agreement for future development of NK Cell Therapy, 2017
    Table 7:Companies of NK cells based therapies financing for future developments, 2017
    Table 8:Companies of NK cells received grants, 2017
    Table 9: Analysis of Natural killer cells on the basis of Designation, 2017
    Table 10: Institute involved in NK Cells, 2017
    Table 11:Companies and their technologies for NK cell therapy, 2017
    Table 12:Natural Killer Cell based therapies -Trial Completion Year, Phase, Drug and Company, 2017
    Table 13:SWOT analysis of NK Cells Based Therapies, 2017
    Table 14:Number of Products Under Development for Natural Killer Cells Therapies, 2017
    Table 15: Number of Products under development by Companies, 2017
    Table 16: Late Stage Products (Phase III and Filed), 2017
    Table 17: Mid Stage Products (Phase II), 2017
    Table 18: Early Stage Products (Phase I), 2017
    Table 19: Pre-Clinical and Discovery Products, 2017
    Table 20: Assessment by Monotherapy Products, 2017
    Table 21:Assessment by Combination Products, 2017
    Table 22: Assessment by Route Of Administration, 2017
    Table 23:Assessment by Stage and Route Of Administration, 2017
    Table 24: Assessment by Molecule Type, 2017
    Table 25: Assessment by Stage and Molecule Type, 2017
    Table 26:Assessment by Stage of development and Domain, 2017
    Table 27:Assessment by Stage of development and Domain, 2017

    Figure 1: Mechanism of action
    Figure 2:Types of NK Cell Receptors and Share of products, 2017
    Figure 3:Percentage Share of NK Cell Therapeutics, 2017
    Figure 4:Target of NK cells and number of products, 2017
    Figure 5:Natural Killer Cell based therapies -Number of Products (N) and Stages of Development,2017
    Figure 6:NK Cells Therapy Collaborations and Deal Year, 2017
    Figure 7:Collaboration and deal value, 2017
    Figure 8: Financing and deal value, 2017
    Figure 9:NK Cells based therapies designation and Number of Products, 2017
    Figure 10: Technologies Involved in NK Cells Based Therapies with their companies, 2017
    Figure 11:Natural Killer Cell based therapies-Study Completion Date, Indication and Recruitment status of Phase III Drugs, 2017
    Figure 12:Natural Killer Cell based therapies-Study Completion Date, Indication and Recruitment status of Phase II Drugs, 2017
    Figure 13:Natural Killer Cell based therapies- Study Completion Date, Indication and Recruitment status of Phase-I Drugs, 2017
    Figure 14:Natural Killer Cell based therapies-Number of Trials (N) and Study Completion Year, 2017
    Figure 15:Leading NK Cells based therapies companies and Shares, 2017
    Figure 16:Number of Products under Development for Natural Killer Cells Therapies,2017
    Figure 17:Late Stage Products (Phase III), 2017
    Figure 18: Mid Stage Products (Phase II), 2017
    Figure 19:Early Stage Products (Phase I), 2017
    Figure 20:Pre-Clinical and Discovery Products, 2017
    Figure 21: Assessment by Monotherapy Products,2017
    Figure 22: Assessment by Combination Products, 2017
    Figure 23: Assessment by Route of Administration, 2017
    Figure 24: Assessment by Stage and Route of Administration, 2017
    Figure 25: Assessment by Molecule Type,2017
    Figure 26: Assessment by Stage and Molecule Type, 2017
    Figure 27: Assessment by Domain, 2017
    Figure 28:Assessmentby Stage and Domain, 2017

    Natural killer cell Therapy Pipeline scenario
    Monalizumab
    NKTT-120
    Ganitumab
    Herceptin
    Rituxan
    Gazyv HER
    Collaborations & Partnering deals
    Lorvotuzumab
    Mogamulizumab
    Glycostem Therapeutics
    Affimed Therapeutics
    AGNKT Therapeutics
    Dynavax
    ? Multimmune GmbH
    ? Kyowa Hakko Kirin Co., Ltd.
    ? Altor BioScience Corporation
    ? ImmunoGen Inc.
    ? Five Prime Therapeutics
    ? Fortress Biotech
    ? Fate Therapeutics
    ? Nantkwest
    • Single User License
      $2,750.00
    • Site License
      $5,500.00
    • Global License
      $8,250.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap